Why has the Cochlear (ASX:COH) share price lost 7% in a month?

The hearing implant giant has had a difficult run of late…

| More on:
a woman puts her fingers in her ears with a pained expression on her face with her eyes closed as though trying to block hearing bad news or an unpleasant loud noise.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cochlear Ltd (ASX: COH) share price started off the week's trading in the red but clawed back 1.88% yesterday to finish at $219.29.

That ends a difficult month for the manufacturer of the revolutionary cochlear hearing implant. The company's share price has slipped a further 7.6% out of the money in the last month, well ahead of the S&P/ASX 200 Index (ASX: XJO)'s loss of just 0.39% in that time.

Whilst there's been no market sensitive information for the company as of late, it's worthwhile taking a look at what's driving Cochlear shares lately.

Why has the Cochlear share price dropped 10% this past month?

If we take a step back and look at what's happened even earlier than September, it's clear Cochlear shares have been stuck in a descending channel since the company released its FY21 earnings results on 20 August.

In its report for FY21, Cochlear recognised a series of positive growth levers that translated directly to its financial performance. For instance, implant unit sales grew 15% year on year to 36,546 while sales revenue came in 10% higher from last year.

This carried through to Cochlear's bottom line. The company recorded a 54% year on year increase in underlying net profit – ahead of company guidance – and a corresponding 60% increase in its full year dividend to $2.55 per share.

These are undoubtedly positive results. However, at the time, the market was left searching for more. It seemed the company's earnings figures – whilst favourable on an absolute basis – where well behind consensus forecasts.

Failing to meet the forecasts of analysts at research and investment firms at earnings time generally spells bad news for a company's share price.

Numerous studies have shown companies who 'miss' analyst's published forecasts during earnings season tend not to perform too well after the fact. That's because investors tend to reward companies who post stronger than expected earnings, anticipating these to carry higher valuations into the future.

By the time September arrived, the Cochlear share price had already given back around 10% since its earnings results roughly two weeks earlier.

A regain in confidence, and perhaps some investors seeing a bargain in the cheaper Cochlear share price, helped prop the company's shares back towards the August highs. However, an announcement late last month regarding a potential patent infringement sent prices marching back down.

According to the University of Pittsburgh, it believes Cochlear has infringed on one of its patents, although the company claims the patent in question is invalid.

Nonetheless, investors were quick to punish Cochlear again, sending its shares a further 9% further into the red. That's a $22 per share loss in a matter of weeks, just to show the rate of decline.

It's also worth noting that the S&P/ASX 200 Health Care index (XHJ) is also 5.61% into the red over the past month as well, indicating weakness in the broader ASX healthcare sector lately.

It appears these factors are weighing on the Cochlear share price over the past few weeks.

Cochlear share price snapshot

The Cochlear share price has climbed almost 16.5% into the green this year to date.

However, over the last 12 months, it is just 1% ahead, well behind the benchmark index's return of around 19% in that time.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

Guess which ASX All Ords stock is rocketing 58% on big US news

What is getting investors excited today? Let's find out.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 reasons to buy this quality ASX 200 healthcare share today

A leading expert expects this outperforming ASX 200 healthcare share will keep running hot.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Brokers tip 4 ASX 200 healthcare shares to buy now

Healthcare is a defensive sector that can provide useful cover for investors when the market is volatile.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

How Trump's tariffs have created 'upside potential' for CSL shares

A leading expert says CSL shares are now looking ‘cheap’.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

Telix shares crash 8% on US FDA blow

This high-flying stock has been hit with some bad news.

Read more »

A man wakes up happy with a smile on his face and arms outstretched.
Healthcare Shares

ResMed shares jump 8% on strong Q3 update

It was yet another strong quarter from this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX All Ords stock is up 10% on big news

This high-flying stock just can't stop rising. What's going on?

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

Telix shares rocket 15% on stellar Q1 sales update

Let's see how the company performed during the three months.

Read more »